PV Bulletin

Changes to Labels and Patient Information Leaflets - Self-Certification Process

The MHRA has issued new guidance allowing Marketing Authorisation Holders to submit certain changes to labels and PILs through a streamlined self-certification process.

PV Impact Brief

Urgency: HighConfidence: high

What changed

Introduction of a self-certification process for labeling updates, allowing for quicker implementation of certain changes to labels and Patient Information Leaflets, unless those changes fall under categories P1-P4 which require a full assessment.

Why it matters

This regulatory update can reduce the time for Marketing Authorisation Holders (MAHs) to implement safety-related changes, thus enhancing patient safety and compliance.

Action needed

MAHs must categorize their proposed label and PIL updates, utilizing the self-certification route for those not requiring full assessment; submissions validated through this route will receive acceptance letters within 14 days.

Relevant for
Regulatory Intelligence LeadLabeling LeadQPPV
Processes impacted
Labeling
Owner

Regulatory Intelligence Lead

Review cadence

Annual review recommended for compliance updates.

Policy change details

Document type
Guideline
Policy status
final
Publication date
2026-07-03
Policy change
New supplementary guidance has been issued by the MHRA regarding the submission of changes to labels and Patient Information Leaflets (PILs) through the self-certification process.

Key changes

Provides additional procedural details and requirements for using the self-certification route for labelling and PIL updates, ensuring faster implementation of administrative and certain safety-related changes.

Affected workflows

Labeling

Responsible groups

Regulatory AffairsPharmacovigilanceSafety Operations

Document identifiers

Supplementary guidance self-certification

PV impact

MAHs can utilize this streamlined process for specific types of labelling updates, potentially reducing the time required to implement safety-related changes in the PIL and on packaging.

View regulator source

Source document details

Exact policy details

Default route for registering changes to labels and leaflets
Self-certification
Applies to: Applicable unless changes fall under categories P1-P4
Regulation 267 of the Human Medicines Regulations (2012) · p. 1 · High · Source
Timeframe for acceptance letter after self-certification submission
14 days
Applies to: After validation of submission
Submission decision tree section · p. 3 · High · Source
Timeline for expedited review for OTC medicines with PAGB
30 days
Applies to: When an optional submission has been made to PAGB
P2 category section · p. 2 · High · Source
Categories requiring full assessment instead of self-certification
P1-P4
Applies to: Proposed updates that fall into these categories
What changes fall into the P1-P4 categories section · p. 2 · High · Source
Supporting documents for self-certification
eCTD documentation
Applies to: Required for all self-certification submissions
How to submit – documentation required section · p. 4 · High · Source

Evidence and confidence

Confidence: highSource updated: Jul 3, 2026

Full briefing

Practical implication

MAHs must categorize their proposed label and PIL updates, utilizing the self-certification route for those not requiring full assessment; submissions validated through this route will receive acceptance letters within 14 days.

The new supplementary guidance from the MHRA outlines a self-certification process for submitting changes to labels and Patient Information Leaflets (PILs). This process is designed to enable faster implementation of administrative and specific safety-related changes, provided those changes do not fall into categories requiring full assessment.

What changed: Introduction of a self-certification process for labeling updates, allowing for quicker implementation of certain changes to labels and Patient Information Leaflets, unless those changes fall under categories P1-P4 which require a full assessment.

Why it matters: This regulatory update can reduce the time for Marketing Authorisation Holders (MAHs) to implement safety-related changes, thus enhancing patient safety and compliance.

Practical implication: MAHs must categorize their proposed label and PIL updates, utilizing the self-certification route for those not requiring full assessment; submissions validated through this route will receive acceptance letters within 14 days.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFood and Drug Administration (FDA) · United States · Updated Jun 29, 2026

eMDR System Enhancements - Production Deployment

Urgency: High

Update electronic safety reporting systems and pharmacovigilance databases to implement new rules to ensure all submissions use GENC 3-letter country codes and include the required fields as of July 20, 2026.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward